Rejected from Brain? The 7 Best Journals to Submit Next

The right next target depends on whether your paper is clinical, translational, or mechanistic, and on how fast you need a decision. Here is the realistic shortlist after Brain.

Source: journal author guidelines, SciRev community data, and Clarivate JCR 2024 (accessed June 2026). Acceptance rates and timelines are approximate and vary by article type.

Annals of Neurology is the closest peer to Brain on the clinical-academic side. Its editors want manuscripts of general interest to academic neurologists, including clinical trials and large-scale studies that inform practice. If Brain liked the rigor but felt the finding was too narrow for its translational remit, Annals is often the natural lateral move rather than a step down.

Neurology, the journal of the American Academy of Neurology, is read by practicing clinicians more than by lab-based researchers. A paper that Brain found insufficiently mechanistic, but that has clear bedside implications, can be a strong fit here. The editorial question shifts from "does this advance disease understanding" to "does this change what a neurologist does in clinic."

JNNP (Journal of Neurology, Neurosurgery and Psychiatry) covers the full span of clinical neurological practice, neurosurgery, and neuropsychiatry, with particular strength in common disorders such as stroke, multiple sclerosis, Parkinson's disease, epilepsy, and peripheral neuropathy. If your work is solidly clinical and disease-focused, JNNP is a credible and reachable target.

Acta Neuropathologica is the venue for mechanism. It publishes disease-mechanism work using human or experimental tissue with molecular, cellular, and morphological techniques. A paper that Brain considered "too basic for our clinical readership" frequently belongs here, where the depth of the mechanism is the point rather than a liability.

eBioMedicine, part of The Lancet Discovery Science family, is the translational option when your work bridges discovery and clinical application across biomedicine, including neurological disease. It is gold open access, so factor the article processing charge into the decision.

Lancet Neurology is the aspirational ceiling. It is even more selective than Brain (acceptance on the order of 10 percent) and wants practice-changing clinical research, phase 3 trials, and definitive diagnostic studies. Aim here only if your study has immediate, large-scale clinical impact. For most Brain rejections it is a longer shot, not the default next step.

Brain Communications is the sister-journal safety net, covered in detail in the cascade section below.

The smartest move after a Brain rejection is not to drop a tier blindly. It is to route the manuscript to the venue whose editorial values match your paper's real strengths. Use the reason for rejection as the routing signal.

Source: journal author guidelines and scope statements (accessed June 2026).

Clinical study rejected for narrow scope or insufficient priority? Move laterally, not down. Annals of Neurology and Neurology are the first targets for clinically definitive work, with JNNP close behind for disease-focused studies. Do not assume a clinical paper that missed Brain needs a much smaller journal; it may simply need a journal whose readership is the right audience for that disease area.

Mechanism-led or translational work rejected for being "too basic" for Brain's clinical remit? Step toward the mechanism journals rather than the clinical ones. Acta Neuropathologica for tissue-and-molecular pathogenesis, eBioMedicine for translational work that bridges discovery and clinic. These editors reward the very depth Brain found off-remit.

Rejected after peer review with named gaps? Fix what the reviewers flagged before targeting anything new, then take your existing reviewer reports with you. Many journals accept transferred reviews, which can shorten the next cycle.

Brain to Brain Communications transfer. Brain offers an optional, efficient transfer to its open-access sister journal Brain Communications when a manuscript is unsuccessful at Brain. This is the cleanest cascade step in the entire neurology portfolio: your files, and any reviewer reports, move across without resubmitting from scratch. Brain Communications publishes preclinical and clinical studies across neurological and psychiatric disease and brain health, with flexible article lengths.

Take the transfer when the science is sound but priority or breadth fell short of Brain and you can fund the gold open-access article processing charge (roughly £2,906, with waivers for authors in low- and middle-income countries and coverage under many OUP Read and Publish agreements). Decline it only if reviewers raised method or cohort concerns you have not yet resolved, because the transfer carries those concerns along with the files.

Before you cascade anywhere, a Brain manuscript fit check can tell you whether the rejection was about scope, clinical significance, or something more fundamental that the next journal will catch too.

Brain editors screen for whether a finding earns its place between basic neuroscience and clinical practice, and that single editorial expectation drives most of what gets returned. The named rejection patterns below come from our pre-submission review work, cross-checked against Brain's own author guidance and SciRev community data on its review timeline. In our pre-submission review work with Brain submissions, four patterns generate the most consistent rejections worth checking your manuscript against before you send it anywhere new.

Pattern 1: Clinical significance asserted but not demonstrated. Brain occupies the bridge between basic neuroscience and practice-facing clinical journals, and its editorial bar requires that a finding visibly changes how the field understands or manages a brain disorder. Across our Brain pre-submission reviews, the most common rejection driver is a discussion section that claims clinical relevance in general terms without tying it to a concrete change in diagnosis, prognosis, or management.

We see this most often when the cohort is real and well-characterized but the manuscript never states, in testable terms, what a neurologist would do differently because of the result. The fix is rarely new data; it is a clinical-significance framing that an editor can act on.

Pattern 2: Cohort or sample-size limitations that undercut the headline claim. Brain's clinical and translational studies are scrutinized for whether the cohort can actually support the conclusion. In manuscripts we review for Brain, the recurring problem is a sample size adequate for a descriptive finding but underpowered for the subgroup or interaction claim that the abstract leads with. Single-center cohorts, convenience samples, and absent or thin replication all surface here.

Check whether your strongest stated claim is the one your cohort and statistical analysis can defend, or whether it sits a tier above what the numbers actually license.

Pattern 3: Scope drift toward basic neuroscience without a clinical bridge. Brain is not Neuron and not Nature Neuroscience. Manuscripts that are mechanistically excellent but never connect the mechanism to a human disease consequence read as off-remit to Brain's clinically anchored editors.

In our pre-submission reviews of mechanism-heavy Brain submissions, the papers that get returned are usually the ones where the methods and figures are entirely cellular or animal-model and the clinical relevance lives in a single speculative paragraph. If that describes your paper, the rejection is a routing signal, not a quality verdict, and Acta Neuropathologica or eBioMedicine is the better home.

Pattern 4: Incremental advance in a well-worked disease area. Brain wants findings that move the field, not confirmations of what the literature already establishes. We repeatedly see Brain submissions that add a competent but confirmatory result to a crowded disease area, where reviewers acknowledge the rigor of the methods and statistical analysis but conclude the advance is incremental. Before resubmitting elsewhere, decide honestly whether the contribution is new enough for a selective journal, or whether it fits a solid specialist venue where the confirmatory value is genuinely useful.

A Brain desk-rejection risk check screens a manuscript against these patterns before an editor does.

Do not just blast the same PDF down the ladder. The fastest path to a second rejection is sending the manuscript that Brain returned, unchanged, to a journal that screens for the same things.

Sometimes the paper needs real work, not just a different cover sheet. A desk rejection on scope grounds needs a reframed abstract, introduction, and cover letter aimed at the new journal's readership, but not new science. A post-review rejection is different: if reviewers named a cohort limitation, a statistical analysis gap, or a missing control, that concern will travel to the next journal because reviewers there look for the same gaps. Close it first, and know when to walk away from a target that is no longer realistic.

Be honest about appeals, too. Appeal only when you can point to a documented factual error in the review, such as a reviewer misreading your primary endpoint. Appeals on grounds of taste or disagreement about novelty rarely succeed and cost you weeks you could spend on the next submission. And if the rejection cited an incremental advance in a crowded area, the hard question is whether the paper belongs at a selective journal at all, or whether a strong specialist venue is the realistic and honest home.